AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10894590 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 weeks of ribavirin/interferon
Number of subjects: 0
Study 10894590 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks of interferon alone
Number of subjects: 0
Study 10894590 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of combination therapy
Number of subjects: 0
Study 10894590 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 weeks of combination therapy
Number of subjects: 0
Study 9004394 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effect estimate under covariate omission or categorization
Number of subjects: 0
Study 9004394 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct adjustment of treatment effect estimate
Number of subjects: 0
Study 9004394 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate omission or categorization
Number of subjects: 0
Study 7801569 — intervention group
Group type: EXPERIMENTAL
Intervention: Specified formula for assessing the volume of the right ventricular outlet section
Number of subjects: 0
Study 7801569 — intervention group
Group type: COMPARATOR
Intervention: Main formula for assessing the volume of the right ventricular outlet section
Number of subjects: 0
Study 6279142 — intervention group
Group type: EXPERIMENTAL
Intervention: Single massive dose of 15 mg vitamin D orally
Number of subjects: 37
Study 6279142 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of 50 micrograms vitamin D for 20 days
Number of subjects: 37
Study 6279142 — intervention group
Group type: COMPARATOR
Intervention: Normal children (control group)
Number of subjects: 37
Study 31343205 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 155
Study 30829516 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone feedback intervention
Number of subjects: 1003
Study 30829516 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter feedback intervention
Number of subjects: 1003
Study 30829516 — intervention group
Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 1003
Study 27867020 — intervention group
Group type: EXPERIMENTAL
Intervention: PO baclofen 20 mg
Number of subjects: 36
Study 27867020 — intervention group
Group type: EXPERIMENTAL
Intervention: IV baclofen 15 mg
Number of subjects: 36
Study 27867020 — intervention group
Group type: COMPARATOR
Intervention: PO baclofen (10 mg, 15 mg, 20 mg)
Number of subjects: 36
Study 27867020 — intervention group
Group type: COMPARATOR
Intervention: IV baclofen (7.5 mg, 11.5 mg, 15 mg)
Number of subjects: 36
Study 26549276 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation diabetes-specific formula (Group A)
Number of subjects: 157
Study 26549276 — intervention group
Group type: COMPARATOR
Intervention: Control diabetes-specific formula (Group C)
Number of subjects: 157
Study 26549276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diabetes-specific formulas (Group A and Group C)
Number of subjects: 157
Study 26549276 — intervention group
Group type: COMPARATOR
Intervention: Standard control formula (Group B)
Number of subjects: 157
Study 23345946 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum (PHGG) at dosage of 5 g/d (n = 30)
Number of subjects: 60
Study 23345946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fruit-juice, n = 30)
Number of subjects: 60
Study 21795652 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help (GSH) plus usual care (UC)
Number of subjects: 127
Study 21795652 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 127
Study 19299778 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5 mg melatonin
Number of subjects: 121
Study 19299778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 17535013 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 209
Study 17535013 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher surgical trainees performing operations
Number of subjects: 209
Study 17535013 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of operation and complication rate
Number of subjects: 209
Study 16169530 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar I disorder subjects (BP-I)
Number of subjects: 8
Study 16169530 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 8
Study 14504664 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol (10 mg tablets twice daily)
Number of subjects: 10
Study 14504664 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (7.5 mg controlled release tablets twice daily)
Number of subjects: 10
Study 14504664 — intervention group
Group type: COMPARATOR
Intervention: Intravenous terbutaline (injected intradermally)
Number of subjects: 10
Study 10490735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide (Pnc PS) vaccine
Number of subjects: 20
Study 10490735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-diphtheria toxoid conjugate vaccine (PRP-D)
Number of subjects: 20
Study 10490735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide (Pnc PS) and Hib-diphtheria toxoid conjugate vaccine (PRP-D)
Number of subjects: 20
Study 8520793 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide aerosol (10 mg)
Number of subjects: 24
Study 8520793 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide aerosol (10 mg four times per day) for 4 weeks
Number of subjects: 24
Study 8520793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8520793 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide treatment over 1 month
Number of subjects: 24
Study 1787680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood
Number of subjects: 72
Study 1787680 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (Control)
Number of subjects: 72
Study 6176322 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP-ABVD and irradiation
Number of subjects: 155
Study 6176322 — intervention group
Group type: COMPARATOR
Intervention: MVVPP
Number of subjects: 155
Study 6176322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 155
Study 31211448 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIB054 (15 or 45 mg/kg)
Number of subjects: 66
Study 31211448 — intervention group
Group type: COMPARATOR
Intervention: BIIB054 (1-135 mg/kg)
Number of subjects: 66
Study 27324516 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (ED) from the day prior to surgery until postoperative day (POD) 3
Number of subjects: 94
Study 27324516 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative diet program
Number of subjects: 94
Study 24676715 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill-based strategy (aspirin 75mg, simvastatin 40mg, lisinopril 10mg, and either atenolol 50mg or hydrochlorothiazide 12.5mg)
Number of subjects: 623
Study 24676715 — intervention group
Group type: COMPARATOR
Intervention: Usual care (separate medications and doses as prescribed by their doctor)
Number of subjects: 623
Study 24676715 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill-based strategy
Number of subjects: 623
Study 23073367 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning-focused interventions (dialogic reading or shared reading)
Number of subjects: 324
Study 23073367 — intervention group
Group type: EXPERIMENTAL
Intervention: Code-focused interventions (phonological awareness, letter knowledge, or both)
Number of subjects: 324
Study 23073367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phonological awareness and letter knowledge interventions
Number of subjects: 324
Study 23073367 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 324
Study 22133251 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity intradialytic aerobic training program 3 times per week for 12 weeks
Number of subjects: 28
Study 22133251 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity constant work rate (CWR) test
Number of subjects: 28
Study 22133251 — intervention group
Group type: COMPARATOR
Intervention: Incremental work rate (IWR) test
Number of subjects: 28
Study 18985382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand position during sequence learning in Experiment 1
Number of subjects: 0
Study 18985382 — intervention group
Group type: EXPERIMENTAL
Intervention: Executing entire sequences by reacting to one cue in Experiment 2
Number of subjects: 0
Study 16143492 — intervention group
Group type: EXPERIMENTAL
Intervention: ImPACT Test Battery
Number of subjects: 72
Study 13678427 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (angiotensin II type I receptor antagonist)
Number of subjects: 90
Study 13678427 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta1‐adrenoceptor blocker)
Number of subjects: 90
Study 11045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of antacid and anti-ulcer drugs during the last month of pregnancy by mothers
Number of subjects: 137
Study 11045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac deceleration during labor and delivery
Number of subjects: 137
Study 11045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding at birth
Number of subjects: 137
Study 11045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean state anxiety score of mothers
Number of subjects: 137
Study 11045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean trait anxiety scores of mothers
Number of subjects: 137
Study 11045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of antacid and anti-ulcer treatments
Number of subjects: 137
Study 11045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac deceleration
Number of subjects: 137
Study 11045833 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 137
Study 8884843 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg/day) for 28 days, vitamin C (2 g/day), and allopurinol (600 mg/day) for 2 days before and 1 day after CABG (Group A)
Number of subjects: 20
Study 8884843 — intervention group
Group type: COMPARATOR
Intervention: All drugs for 3 days (Group C)
Number of subjects: 20
Study 8884843 — intervention group
Group type: COMPARATOR
Intervention: Corresponding controls (Group B)
Number of subjects: 20
Study 8884843 — intervention group
Group type: COMPARATOR
Intervention: Corresponding controls (Group D)
Number of subjects: 20
Study 1533528 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg isradipine twice daily
Number of subjects: 174
Study 1533528 — intervention group
Group type: COMPARATOR
Intervention: 40 mg diltiazem thrice daily
Number of subjects: 174
Study 6691394 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (12 mg)
Number of subjects: 144
Study 6691394 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (250 mg)
Number of subjects: 144
Study 6691394 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (125 mg)
Number of subjects: 144
Study 6691394 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 31383509 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery embolization (RAE)
Number of subjects: 15
Study 29436324 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to low-intensity CBT intervention
Number of subjects: 142
Study 29436324 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to low-intensity CBT intervention
Number of subjects: 142
Study 26982815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv (125 mg b.i.d. for one week, then escalating to a maximum tolerated dose up to 250 mg b.i.d.)
Number of subjects: 596
Study 26982815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study 26982815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv
Number of subjects: 596
Study 24786192 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation with high water activity
Number of subjects: 0
Study 24786192 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation with urea
Number of subjects: 0
Study 24786192 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation with glycerol
Number of subjects: 0
Study 24786192 — intervention group
Group type: COMPARATOR
Intervention: Topical formulation with low water activity
Number of subjects: 0
Study 21904296 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of milk expression within 60 min after delivery
Number of subjects: 20
Study 21904296 — intervention group
Group type: COMPARATOR
Intervention: Initiation of milk expression between 1 to 6 hours after delivery
Number of subjects: 20
Study 21194471 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal replacement (HP) providing 2.2 g protein/kg of lean body mass (LBM)/day
Number of subjects: 100
Study 21194471 — intervention group
Group type: COMPARATOR
Intervention: Standard protein meal replacement (SP) providing 1.1 g protein/kg LBM/day
Number of subjects: 100
Study 17478542 — intervention group
Group type: EXPERIMENTAL
Intervention: Indian HB vaccine (GeneVac‐B)
Number of subjects: 262
Study 17478542 — intervention group
Group type: EXPERIMENTAL
Intervention: European HB vaccine (Engerix‐B)
Number of subjects: 262
Study 17478542 — intervention group
Group type: COMPARATOR
Intervention: Both vaccines
Number of subjects: 262
Study 15630104 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management group (n = 368)
Number of subjects: 737
Study 15630104 — intervention group
Group type: COMPARATOR
Intervention: Conventional management group (n = 369)
Number of subjects: 737
Study 11336429 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 1821
Study 11336429 — intervention group
Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 1821
Study 12596840 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help module
Number of subjects: 98
Study 12596840 — intervention group
Group type: COMPARATOR
Intervention: Routine counseling
Number of subjects: 98
Study 8155448 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 60
Study 8155448 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 60
Study 8155448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2844467 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐9780 (1 mg administered intravenously)
Number of subjects: 16
Study 2844467 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg administered orally)
Number of subjects: 16
Study 2844467 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects (mild headache and light-headedness)
Number of subjects: 16
Study 29360570 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress
Number of subjects: 158
Study 29360570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor‐α
Number of subjects: 158
Study 29360570 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress and tumor necrosis factor‐α
Number of subjects: 158
Study 29360570 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 158
Study 28049491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg per day
Number of subjects: 42
Study 28049491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25744873 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol smokers
Number of subjects: 186
Study 25744873 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol smokers with higher levels of dependence
Number of subjects: 186
Study 25744873 — intervention group
Group type: EXPERIMENTAL
Intervention: FTND
Number of subjects: 186
Study 23053692 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention with aftercare (MD)
Number of subjects: 203
Study 23053692 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (AE)
Number of subjects: 203
Study 23053692 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 203
Study 21177013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (n = 42)
Number of subjects: 81
Study 21177013 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (n = 39)
Number of subjects: 81
Study 18326602 — intervention group
Group type: EXPERIMENTAL
Intervention: CARB-B (breakfast intervention)
Number of subjects: 23
Study 18326602 — intervention group
Group type: EXPERIMENTAL
Intervention: CARB-L (lunch intervention)
Number of subjects: 23
Study 18326602 — intervention group
Group type: EXPERIMENTAL
Intervention: CARB-D (dinner intervention)
Number of subjects: 23
Study 18326602 — intervention group
Group type: EXPERIMENTAL
Intervention: CARB-E (even distribution intervention)
Number of subjects: 23
Study 16549962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine monotherapy (300 mg once daily)
Number of subjects: 58
Study 16549962 — intervention group
Group type: COMPARATOR
Intervention: Complete therapy interruption (TI group)
Number of subjects: 58
Study 12665739 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing
Number of subjects: 224
Study 10561655 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized interpretation of nonstress test results
Number of subjects: 404
Study 10561655 — intervention group
Group type: COMPARATOR
Intervention: Visual interpretation of nonstress test results
Number of subjects: 404
Study 8730978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg
Number of subjects: 12
Study 8730978 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Number of subjects: 12
Study 8730978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1872132 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Indometacin
Number of subjects: 49
Study 1872132 — intervention group
Group type: COMPARATOR
Intervention: 0.1% Dexametason
Number of subjects: 49
Study 6866594 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (demonstration of the Brazelton Neonatal Assessment Scale)
Number of subjects: 75
Study 6866594 — intervention group
Group type: COMPARATOR
Intervention: Control groups (two control groups)
Number of subjects: 75
Study 29121408 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW support
Number of subjects: 244
Study 29121408 — intervention group
Group type: COMPARATOR
Intervention: No CHW support
Number of subjects: 244
Study 25971439 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of 25(OH)D
Number of subjects: 1340
Study 25971439 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of FGF23
Number of subjects: 1340
Study 24292412 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation programme
Number of subjects: 81
Study 24292412 — intervention group
Group type: COMPARATOR
Intervention: Parent counselling and support intervention
Number of subjects: 81
Study 22250997 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood education treatment
Number of subjects: 101
Study 20732609 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game training
Number of subjects: 91
Study 20732609 — intervention group
Group type: COMPARATOR
Intervention: Card-sort exercise
Number of subjects: 91
Study 20732609 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 91
Study 18294750 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide (bleaching group)
Number of subjects: 36
Study 18294750 — intervention group
Group type: COMPARATOR
Intervention: Saliva (control group)
Number of subjects: 36
Study 15923508 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar anaesthesia
Number of subjects: 39
Study 15923508 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival anaesthesia
Number of subjects: 39
Study 12888049 — intervention group
Group type: COMPARATOR
Intervention: Normal room air breathing
Number of subjects: 22
Study 12888049 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxic hypercapnia
Number of subjects: 22
Study 10619580 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 268
Study 10619580 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 268
Study 10619580 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 268
Study 10619580 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg vs 16 mg
Number of subjects: 268
Study 10619580 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 268
Study 7568642 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal pulse amplitude
Number of subjects: 0
Study 7568642 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal blood volume
Number of subjects: 0
Study 7568642 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance
Number of subjects: 0
Study 7568642 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 0
Study 7568642 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sexual arousal
Number of subjects: 0
Study 7568642 — intervention group
Group type: EXPERIMENTAL
Intervention: Body sensations
Number of subjects: 0
Study 7568642 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional experience
Number of subjects: 0
Study 1777373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of dermatan sulphate (200 mg)
Number of subjects: 12
Study 1777373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of dermatan sulphate (100 and 300 mg)
Number of subjects: 12
Study 1777373 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of dermatan sulphate (1 g)
Number of subjects: 12
Study 7028071 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate preceded 10 minutes earlier by inhalation of salbutamol
Number of subjects: 60
Study 7028071 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beclomethasone dipropionate followed 10 minutes later by salbutamol
Number of subjects: 60
Study 6490470 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water (n = 8)
Number of subjects: 29
Study 6490470 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-treated tap water (n = 11)
Number of subjects: 29
Study 6490470 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-treated flavored tap water (n = 10)
Number of subjects: 29